Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib DDI with Itraconazole and Rifampin in Advanced Solid Tumors
NCT03077607Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of talazoparib in ovarian carcinoma, cervical adenocarcinoma, Small Cell Lung Cancer (SCLC) and 1 more (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at Day 25, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at Day 25 and 1 more. Started Nov 2016; status: completed.
02
Drugs
talazoparib
03
Conditions
ovarian carcinomacervical adenocarcinomaSmall Cell Lung Cancer (SCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03077607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03077607.